Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. Read More
As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. Read More
To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” Read More
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. Read More
Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). Read More
Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. Read More
Despite the Biosecure Act’s five-year wind-down period that isn’t expected to start until mid-2028, Wuxi Apptec is already feeling the repercussions of being added last month to the U.S. Department of War’s Section 1260H list. Read More
The data mill continues to churn out encouraging results in pancreatic ductal adenocarcinoma (PDAC), with shares of Ramat Gan, Israel-based Can-Fite Biopharma Ltd. benefiting from the latest, phase IIa dispatch that pushed shares (NYSE:CANF) up 58%, or $1.73, to close July 1 at $4.70. Read More
The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are conducted at Chinese military hospitals and in Xinjiang, China. Read More
After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? With developments accelerating in the field, BioWorld's special series explores the advancements in the space, looking at the implanted technologies, their potential to transfer care, what’s driving investor interest and the challenges ahead. Read More
Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Abbisko, Aimedbio, ALR Technologies, Aptose, Astrazeneca, Ayumi, Best Praise, CSPC, Eli Lilly, Fosun Wanbang, GNI, Hanmi, Innovent, Inocras, Insilico Medicine, Junshi, Kyowa Kirin, Orion, Shilpa Biologicals, SK Bioscience, Takeda, Universe. Read More
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Cansino, Daiichi Sankyo, Eisai, Hengrui, Hutchmed, Kowa, Novaliq, Nuvation. Read More
